Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 4/20 | 0.31 |
| ▸ | CA2 | P00918 | 4/20 | 0.31 |
| ▸ | CA12 | O43570 | 3/20 | 0.31 |
| ▸ | CA9 | Q16790 | 3/20 | 0.31 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 2/20 | 0.30 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.30 |
| ▸ | PHGDH | O43175 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.30 |
| ▸ | FBP1 | P09467 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7758216 | 0.98 | HTT (0.34) | HTTCA1CA2CA12CA9 | |
| SCHEMBL3074878 | 0.98 | HTT (0.38) | HTTCA1CA2CA12CA9 | |
| SCHEMBL3066005 | 0.95 | HTT (0.35) | HTTCA1CA2CA12CA9 | |
| Ammonia Solution, Strong SCHEMBL28405557 | 0.93 | HTT (0.34) | HTTCA1CA2CA12CA9 | |
| SCHEMBL10897991 | 0.91 | HTT (0.42) | HTTCA1CA2CA12CA9 | |
| SCHEMBL3071699 | 0.91 | HTT (0.42) | HTTCA1CA2CA12CA9 | |
| SCHEMBL28146447 | 0.88 | HTT (0.41) | HTTCA1CA2CA12CA9 | |
| SCHEMBL3074808 | 0.88 | — | — | |
| Piperidine SCHEMBL28394461 | 0.86 | ALDH1A1 (0.33) | HTTCA2ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL4747013 | 0.85 | ALDH1A1 (0.38) | HTTCA1CA2CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050008568-A1 | Technetium or rhenium complexes, radiopharmaceutical products comprising them | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-01-13 | — | — | US | disclosed |
| EP-1453841-A1 | TECHNETIUM OR RHENIUM COMPLEXES, RADIOPHARMACEUTICAL PRODUCTS COMPRISING THEM | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-09-08 | — | — | EP | disclosed |
| WO-2003044031-A1 | TECHNETIUM OR RHENIUM COMPLEXES, RADIOPHARMACEUTICAL PRODUCTS COMPRISING THEM | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050008568-A1 | Technetium or rhenium complexes, radiopharmaceutical products comprising them | TSHR, MRPS35, TFRC | HTT 1573/4885CA1 2501/4885CA2 1554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.